Quantcast

Latest Dopamine agonists Stories

2010-01-12 07:00:00

WALTHAM, Mass., Jan. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's extended-release formulation of pramipexole (pramipexole ER), which launched late last year in Europe and is expected to launch this year in the United States, will garner peak year sales of $250 to $500 million in the world's major pharmaceutical markets. The Pharmacor finding from the topic...

2010-01-11 19:55:43

In a world first, researchers identify and define dopamine agonist withdrawal syndrome, or DAWS New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by...

2009-12-21 13:30:00

Clinical study seeks to validate dyskinesia clinical scales, lowering hurdle to industry investment in new treatments NEW YORK, Dec. 21 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's...

2009-12-09 03:24:00

LONDON, Dec. 9 /PRNewswire/ -- The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. With the introduction of newer dopamine agonists as well as fresh recommendations and treatment guidelines that call for using dopamine agonists as first-line therapy, the market is experiencing a...

2009-11-19 08:00:00

MUNSTER, Germany, November 19 /PRNewswire/ -- MONITORING FORCE GmbH announced that they have filed on November 16th, 2009 Flibanserin in the indication treatment-relevant levodopa-induced dyskinesia in Parkinson's disease for orphan drug status designation with the European Medicines Agency (EMEA). Levodopa-induced dyskinesia is a complication of the mainstay treatment in advanced Parkinson's and a serious burden to some of those affected, since it may be disabling for the patients and...

2009-11-18 10:40:32

Australian scientists have significantly advanced our understanding of dopamine release from nerve cells, findings that should speed the development of more effective drugs for treating Parkinson's Disease. People with Parkinson's Disease suffer from muscle rigidity, tremor, a slowing of physical movement and, in extreme cases, a loss of physical movement. These primary symptoms are caused by the loss of dopamine producing nerve cells in the brain. Medicines used for treating Parkinson's...

2009-11-12 12:31:20

Enhancing the effects of the brain chemical dopamine influences how people make life choices by affecting expectations of pleasure, according to new research from the UCL Institute of Neurology. The study, published today in Current Biology, confirms an important role for dopamine in how human expectations are formed and how people make complex decisions. It also contributes to an understanding of how pleasure expectation can go awry, for example in drug addiction. Dopamine is a...

2009-08-17 08:33:00

The U.S. Food and Drug Administration announced the recall of a Barr Laboratories Inc. amphetamine product because of a health hazard. The FDA said the dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate 20mg mixed amphetamine salt tablets are being recalled because some might exceed weight requirements, resulting in super-potency. The federal agency said potential adverse reactions to a supratherapeutic dose could include cardiovascular,...

2009-08-04 08:00:00

SALT LAKE CITY, Aug. 4 /PRNewswire/ -- RIESTER creative from Utah's End Meth Now campaign has been selected by the Office of National Drug Control Policy (ONDCP) to become a key resource to states across the country in the fight against meth use. In contrast to other approaches combating meth addiction, the End Meth Now campaign inspires hope and enlists the help of loved ones in fighting the drug. "We've had the privilege of working on many successful campaigns, but feel extremely proud...

2009-07-07 23:39:31

With patience, there is hope for recovery from methamphetamine addiction, U.S. researchers say. The study, published in the Journal of Substance Abuse Treatment, says it takes at least one year for former methamphetamine users to regain cognitive functions like impulse control and attentional focus. We used to think most, if not all, effects of meth addiction were permanent, lead study author Ruth Salo of the University of California, Davis, said in a statement. This study adds to the...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.